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Abstract Cystic fibrosis-related diabetes (CFRD) is the most
significant extra-pulmonary comorbidity in cystic fibrosis (CF)
patients, and accelerates lung decline. In addition to the tradi-
tional view that CFRD is a consequence of fibrotic destruction
of the pancreas as a whole, emerging evidence may implicate a
role for cystic fibrosis transmembrane-conductance regulator
(CFTR) in the regulation of insulin secretion from the pancre-
atic islet. Impaired first-phase insulin responses and glucose
homeostasis have also been reported in CF patients. CFTR
expression in both human and mouse beta cells has been con-
firmed, and recent studies have shown differences in endocrine
pancreatic morphology from birth in CF. Recent experimental
evidence suggests that functional CFTR channels are required
for insulin exocytosis and the regulation of membrane potential
in the pancreatic beta cell, which may account for the impair-
ments in insulin secretion observed in many CF patients. These
novel insights suggest that the pathogenesis of CFRD is more
complicated than originally thought, with implications for dia-
betes treatment and screening in the CF population. This re-
view summarises recent emerging evidence in support of a
primary role for endocrine pancreatic dysfunction in the devel-
opment of CFRD.
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Summary
• CF is an autosomal recessive disorder caused by muta-
tions in the CFTR gene
• The vast majority of morbidity and mortality in CF re-
sults from lung disease. However, CFRD is the largest
extra-pulmonary co-morbidity and rapidly accelerates
lung decline
• Recent experimental evidence shows that functional
CFTR channels are required for normal patterns of first-
phase insulin secretion from the pancreatic beta cell
• Current clinical recommendations suggest that insulin is
more effective than oral glucose-lowering drugs for the
treatment of CFRD. However, the emergence of CFTR
corrector and potentiator drugs may offer a personalised
approach to treating diabetes in the CF population
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Introduction
Cystic fibrosis (CF) is the most common autosomal recessive
disorder in white people, and results from mutations in the
cystic fibrosis transmembrane-conductance regulator (CFTR)
gene, located on the long arm of chromosome 7 in humans
[1]. CFTR is an apical membrane Cl− channel that controls
epithelial fluid and salt secretion, wheremutations inCFTR lead
to dehydrated, acidic secretions, which drive CF disease [2].
CFTR is highly expressed in the intestines, pancreas, lungs,
sweat glands and kidneys. The CFTR protein is a 1,480-amino-
acid structure, consisting of two homologous halves, with each
half consisting of six membrane-spanning segments and a nu-
clear binding domain (NBD) [3]. Like other integral membrane
proteins, CFTR is synthesised in the endoplasmic reticulum
(ER) and moves to the Golgi before being trafficked to the
apical membrane [4]. Approximately 77% of the protein re-
sides in the cytoplasm, 19% spanning the membrane and 4%
in an extracellular loop [5]. Of the thousand or so CFTR mu-
tations that have been identified, approximately 20 are under-
stood to be disease causing and are categorised into five classes
of mutations of increasing disease severity, as summarised in
Fig. 1. The most commonly reported mutation results from a
phenylalanine deletion at position 508 (F508del), with at least
one allelic copy of this mutation present in 70–90% of patients
with CF [2]. Class II mutations, including F508del, result from
misprocessing of CFTR in the ER, leading to an absence of
functional protein at the plasmamembrane. Class III mutations,
such as G551D (which is reported in approximately 5% of CF
patients), are correctly processed and trafficked to the plasma
membrane, but lack stability at the apical membrane [6].
Clinical implications of CFTR mutation
Lung disease is the primary cause of morbidity and mortality
among CF patients and results from recurrent and chronic
bacterial infection. However, CF-related diabetes (CFRD) is
the most common extra-pulmonary comorbidity, with patients
presenting with worsened pulmonary function, a greater fre-
quency and severity of pulmonary exacerbations and a greater
prevalence of bacteria in the sputum [7]. In CF patients, pul-
monary exacerbations usually result from bacterial or viral
infections, which are often associated with cough and in-
creased morbidity for the patient. Culturing Pseudomonas
aeruginosa (the primary colonising bacterium in the CF lung)
on medium containing glucose at levels found in CF airways
(~59% of systemic levels) rather than glucose levels found in
the airways of healthy individuals (~10% of systemic levels)
results in a significant increase in bacterial proliferation [8].
While diabetes is a systemic condition affectingmany organs,
the lung is not usually considered an end target of the disease.
However, a community-based cross-sectional study of 11,262
adults, 1,100 of whom had type 2 diabetes and none of whom
had a diagnosis of any chronic lung disease, discovered that
diabetes was associated with a restrictive defect and a 2–4%
decrease in lung function [9]. Consistent with this, a prospective
study of 4,434 men concluded that restrictive lung defects were
associated with type 2 diabetes [10].
Clinically, CF patients diagnosed with CFRD have a six
times greater risk of premature death compared with CF pa-
tients without diabetes [1]. Current estimates suggest that
CFRD is present in approximately 2% of children, 19% of
adolescents and 50% of adults with CF [11]. Moreover, the
rapidly increasing incidence in recent years [11] may be attrib-
uted to enhanced screening programmes and/or advances in CF
management. Although CFRD does not commonly present un-
til adulthood, altered glucose homeostasis is often observed in
childhood [12]. Oral glucose tolerance testing of 240 CF pa-
tients with and without overt diabetes demonstrated that pa-
tients with elevated glucose at 60 min had significantly reduced
pulmonary function and increased HbA1c. In addition, patients
with low plasma insulin at 60 min had significantly decreased
pulmonary status and lower BMI. In all patients, pulmonary
function was higher in patients with higher insulin levels at
60 min, irrespective of high or low glucose [13].
Patients with CFRD also have reduced height and weight
[1] and chronically elevated protein catabolism compared
with patients with CF and no diabetes. The elevation in protein
catabolism may be successfully treated with exogenous insu-
lin [1]. However, frequent illness, coupled with glucocorticoid
use, means that insulin requirements in CFRD patients can be
two or three times that of non-CF patients [14]. It has been
proposed that loss of the anabolic effects of insulin can lead to
subsequent protein catabolism which, in turn, causes clinical
deterioration [14].
Islet-intrinsic defects associated withCFTRmutation
The exact cause(s) of diabetes in CF patients remains unclear,
although it is accepted that patients homozygous for F508del
are most susceptible to developing CFRD [2], with sugges-
tions that this may arise as a result of ER-stress-mediated
apoptosis of the beta cell [15]. However, most CF patients
demonstrate abnormalities in glycaemic control regardless of
the class and severity of the CFTR mutation. Consistent with
this, impaired first-phase insulin response has been reported in
the absence of functional CFTR in both animal [16, 17] and
human [18] studies.
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CFTR mutations reduce bicarbonate-rich secretions from
pancreatic ducts. This facilitates auto-digestion of the sur-
rounding pancreatic tissue, leading to fibrosis and loss of both
the exocrine and endocrine pancreatic tissue [19]. However,
autopsy evidence from children and adolescents with CF sug-
gests that abnormalities in beta cell size and shape can exist
without any reported CFRD or exocrine fibrosis [20, 21].
Lombardo et al reported no change in exocrine pancreatic
function in a group of CF patients over a 13 year study period,
despite a significant increase in the prevalence of diabetes
[22]. These clinical observations, coupled with recent func-
tional studies in beta cell lines [23] and primary beta cells from
mice [17] and humans [24], are consistent with the view that
CFTR deficiency leads to islet-intrinsic defects in insulin
secretion.
Several groups have reported CFTR expression [24–26] and
small CFTR currents in human and mouse beta cells [24] and
the RINmF5 beta cell line [26]. Pancreatic beta cells respond to
a wide range of physiological and pharmacological modulators
of insulin secretion, and many pathways controlling insulin
secretion depend on beta cell ionic flux [27]. For example, a
critical step in glucose-induced insulin secretion involves clo-
sure of ATP-sensitive K+ (KATP) channels which, in turn, elicits
membrane depolarisation and opening of voltage-gated Ca2+
channels. This rapid influx of Ca2+ then triggers a series of
events leading to membrane fusion of insulin-containing secre-
tory vesicles and insulin release [28]. ATP-sensitive K+ chan-
nels are also a target for insulin-releasing drugs, including the
sulfonylureas [29]. Other nutrients also rely on pathways in-
volving ionic flux to stimulate insulin release, including
metabolisable and non-metabolisable amino acids, and amino
acids co-transported with Na+ [30].
While most research to date has focussed on the role of
cationic flux in beta cell function, much less attention has been
directed to the movement of anions such as Cl− [31]. In addi-
tion to the emerging role of CFTR, there are a number of Cl−
channels in the beta cell that are important for function. For
example, C1C-3 is expressed on the secretory granule mem-
brane and is implicated in the maintenance of granular pH.
Inhibition of C1C-3 significantly decreased insulin granule
exocytosis in mouse beta cells [32]. More recently, anotamin-
1 (ANO1), a voltage-sensitive Ca2+-activated Cl− channel, was
found to play a role in glucose-induced insulin secretion from
rat beta cells. Inhibition of ANO1 significantly reduced insulin
release in response to glucose and resulted in a partial
repolarisation of the beta cell [33].
Work in animal models has highlighted the potential of
islet-intrinsic defects associated with CFTR deficiency or
mutation. Evidence from newly established pig [34] and
ferret [16] models suggest that the basic CFTR mutation
has a pronounced effect on islet size and distribution in
neonates. Olivier et al [16] reported reduced first-phase in-
sulin secretion and abnormal glucose tolerance in fasted
newborn CFTR−/− ferrets, a phenotype notably similar to
CF human infants [16]. Stalvey et al [35] reported impaired
glucose tolerance (consistent with observations in CFRD
patients) in CFTR−/− mice exposed to streptozotocin.
However, CFTR− /− mice that were not exposed to
streptozotocin displayed normal glucose tolerance compared
with controls.
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Fig. 1 Classification of CFTR
mutations. Approximately 1,000
CFTR mutations have now been
identified. In the region of 20 of
these mutations are thought to be
disease causing and can be
classified according to the
resulting effect on CFTR protein
production. Broadly speaking,
class I mutations are associated
with more severe phenotypes than
class V mutations, although in
CF, as with other complex genetic
conditions, genotype does not
always predict phenotype
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In the past 2 years, experimental data from isolated primary
beta cells, beta cell lines and transgenic animal models have
identified potential mechanisms that surround the reduction in
insulin secretion associated with CFTR deficiency (summarised
in Fig. 2). Consistently, insulin secretion is reduced in the ab-
sence of functional CFTR channels as in, for example, studies
using isolated beta cells exposed to CFTR inhibitors such as
3-[(3-triflouromethyl)phenyl]-5-[(4-carboxyphenyl)methylene]-
2-thioxo-4-thiazolidinone (CFTRInh-
172) and CFTR inhibitor II
(GlyH-101) [23, 24, 26, 36], studies in CFTR-deficient cell lines
[23] and studies on islets from F508del mutant mice [26]. In
primary human beta cells, insulin granule exocytosis in response
to the cAMP agonists forskolin and glucagon-like peptide 1
(GLP-1) (which activate CFTR through the protein kinase A
[PKA] pathway)was significantly decreased following treatment
with CFTRInh-
172 andGlyH-101 [24]. Onmeasurement ofmem-
brane depolarisations, this effect was most prominent in the ini-
tial depolarisations, which is in line with the decreased first-
phase insulin secretion reported in CFRD patients [24]. This
study also reported a novel role for CFTR as a regulator of
ANO1. CFTR was shown to act upstream of ANO1, which
played a contributory role in the regulation of insulin secretion
from the beta cell, consistent with recent observations [33].
In addition to reductions in insulin secretion in response to
cAMP activators, two independent studies have reported re-
ductions in glucose-induced insulin secretion in models with
CFTR interference [23, 26]. The CFTR inhibitor CFTRInh-
172
affected beta cell resting membrane potential and Ca2+ flux in
RINmF5 cells [26]. MIN6 cells in which CFTR was silenced
using short hairpin (sh)RNA also displayed a significant re-
duction in the ATP:ADP ratio, and this was associated with
reduced glucose-induced insulin secretion [23]. These results
suggest that the first-phase insulin response to glucose ob-
served in CFRD patients may be partly attributable to re-
sponses mediated by membrane-bound voltage-dependent
channels. Further investigations in an F508del mouse model
confirm a significant reduction in glucose-induced insulin se-
cretion in islets studied ex vivo. However, in contrast to the
findings of the above studies, the authors concluded that the
observed reduction in insulin secretion was directly propor-
tional to the reduction in insulin content, and did not occur as a
result of a CFTR-induced beta cell insulin secretory defect per
se [17]. Despite a consistent reduction in insulin secretion,
these preliminary studies merit the need for further mechanis-





























Fig. 2 Potential mechanisms by which CFTR regulates insulin secretion
from the beta cell. Glucose enters the beta cell through GLUT2 and is
rapidly metabolised to glucose 6-phosphate, ultimately resulting in the
generation of ATP, which causes the ATP-sensitive KATP channel to close.
Membrane depolarisation and opening of voltage-dependent Ca2+ chan-
nels (VDCCs) ensue and calcium fluxes into the cell, resulting in insulin
exocytosis. Recent studies have suggested that this process is hampered in
the absence of CFTR, which may result from defects in ATP-generated
cAMP activation of the CFTR channel. Indeed, pronounced reductions in
insulin secretion are observed in response to forskolin- and GLP-1-stim-
ulated increases in cAMP level. In addition, evidence suggests that CFTR
(in conjunction with ANO1) may be involved in the priming of the insulin
granule or in the regulation of calcium flux within the beta cell. The
regulation of ANO1 byCFTR is denoted by the horizontal arrow between
the two channels; dotted lines represent proposed mechanisms yet to be
confirmed
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Given the dominant role of the insulin-secreting beta cell in
diabetes pathogenesis, it is perhaps not surprising that beta
cells have been the first target for preliminary investigations
into the role of CFTR expression in CFRD. However, irregu-
larities in circulating glucose can, of course, be a consequence
of altered insulin, glucagon or somatostatin secretion [22].
While histological examination of autopsy material from pa-
tients with CFRD shows decreased beta cell mass [20, 21], the
effect of the CFTR mutation on alpha and delta cells is less
well studied [37]. Secretion of somatostatin appears to be
preserved in CFRD [25]. Notably, CFTR expression has been
reported in the alpha cells of the islets of Langerhans [37, 38]
with few reports on CFTR localisation in delta cells. Many
islet researchers studying ionic flux and hormone secretion in
beta cells have begun to consider whether CFTR may impact
on glucagon secretion. Glucagon is secreted by the alpha cells
in response to hypoglycaemia, via processes inhibited by in-
sulin and somatostatin [39]. Some evidence suggests that
chronic hyperglycaemia may lead to decreased alpha cell ac-
tivity [40], resulting in reduced islet glucagon secretion [41].
While impaired glucagon secretion is a common finding in CF
[37], no difference in plasma glucagon was found between CF
and non-CF fasted newborn pigs, despite impaired insulin
secretion [34]. These initial observations prompt further inves-
tigations focussed on elucidating the effects of mutant CFTR
on glucagon secretion and the alpha cell.
Future directions and clinical implications
Sulfonylureas are often used as a first-line treatment in type 2
diabetes, as they increase insulin release from beta cells.
Interestingly, sulfonylurea receptor 1 (SUR1), like CFTR, is
a member of the ABC transporter superfamily of proteins, and
shares significant homology with CFTR [29]. As such, com-
pounds that open SUR1 and promote insulin transport may
also act to decrease Cl− transport in CFTR. Conversely, certain
sulfonylureas may also increase the length of time that CFTR
channels are in the activated state, thereby enhancing Cl−
movement across the cell membrane. In a study of 45 CFRD
patients using either insulin or glibenclamide, no difference
was found in forced expiratory volume in 1 s (FEV1), forced
vital capacity (FVC) or weight to height ratio [42]. However,
patients using sulfonylureas reported a better quality of life
and decreased HbA1c and their blood glucose levels were
comparable with those of the insulin group. The efficacy of
glibenclamide failed after an average of 18 months in these
patients, who then commenced insulin therapy [42]. However,
the first-line treatment for CFRD is usually insulin and, de-
spite the apparent success of sulfonylurea treatment in the
above study, current clinical guidelines suggest that insulin
is more effective than oral glucose-lowering agents for the
treatment of CFRD [43].
The development of CFTR correctors and potentiators of-
fers great hope to CF patients and their families. These drugs
act to correct the basic defect in CF and offer a personalised
approach to the treatment of this debilitating disease. Currently,
several corrector or potentiator treatments are licensed for the
treatment of different CFTR mutations, including Ivacaftor,
which targets the class III mutation G551D, and Lumacaftor,
which targets the most common class II mutation, F508del.
While the effect of these drugs on the progression of CFRD
has been poorly studied to date, promisingly, a pilot study that
investigated insulin function and the metabolic impact of
Ivacaftor on CF patients carrying the G551Dmutation reported
improvements in glucose tolerance, with restoration of insulin
responsiveness, particularly in younger participants [12].
While many aspects of CF pathology have been studied in
detail and are well understood, it is only recently that attention
has been directed towards the mechanisms underlying the as-
sociation of diabetes with CF. Preliminary investigations have
begun to unveil a potentially important role for pancreatic islet
cells in the complex pathogenesis of CFRD, opening exciting
new avenues of research with significant clinical potential.
Future detailed studies focussing on the impact of CFTR in
the regulation of endocrine pancreatic function offer great
promise in understanding the fundamental molecular and met-
abolic basis and consequences of CFRD. These studies should
directly impact on the therapeutic management of this hugely
debilitating condition.
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